Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 6
2002 1
2003 11
2004 9
2005 10
2006 14
2007 13
2008 20
2009 16
2010 18
2011 8
2012 9
2013 12
2014 13
2015 10
2016 7
2017 5
2018 3
2019 8
2020 10
2021 6
2022 9
2023 7
2024 8
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, Fichtl M, Belda JI, Hommer A, Laganovska G, Schweitzer C, Voykov B, Zarnowski T, Holló G. Stalmans I, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):179-190. doi: 10.1007/s00417-023-06192-0. Epub 2023 Aug 24. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37615697 Free PMC article. Clinical Trial.
PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda( )) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort( )) ophthalmic solution in the treatment of op …
PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solutio …
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies.
Weinreb RN, Bacharach J, Brubaker JW, Medeiros FA, Bejanian M, Bernstein P, Robinson MR. Weinreb RN, et al. J Ocul Pharmacol Ther. 2023 Jan-Feb;39(1):55-62. doi: 10.1089/jop.2022.0137. Epub 2022 Nov 15. J Ocul Pharmacol Ther. 2023. PMID: 36378864 Free PMC article. Clinical Trial.
Purpose: To evaluate the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops. ...Results: A total of 372 patients received the 10-mug bimatoprost …
Purpose: To evaluate the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that …
A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.
Mansberger SL, Fechtner R, Lopez K, Hubatsch D. Mansberger SL, et al. Contemp Clin Trials. 2024 Dec;147:107730. doi: 10.1016/j.cct.2024.107730. Epub 2024 Oct 28. Contemp Clin Trials. 2024. PMID: 39477206 Clinical Trial.
PURPOSE: To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design. ...CONCLUSION: Both concentrati …
PURPOSE: To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase …
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 g and Selective Laser Trabeculoplasty.
Kolko M, Tatham AJ, Lim KS, Wells AP, Shiu M, Uy HS, Sarkisian SR Jr, Ho Q, Jiao J, Kim K, Goodkin ML, Bejanian M, Robinson MR, Paauw JD; ATHENA STUDY GROUP. Kolko M, et al. Am J Ophthalmol. 2025 Apr;272:19-37. doi: 10.1016/j.ajo.2024.12.026. Epub 2025 Jan 10. Am J Ophthalmol. 2025. PMID: 39800203 Free article. Clinical Trial.
PURPOSE: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to 2 bimatoprost implant administrations versus selective laser trabeculoplasty (SLT). DESIGN: Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, …
PURPOSE: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to 2 bimatoprost implant administrations versus …
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.2 …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.
Lee SS, Burke J, Shen J, Almazan A, Orilla W, Hughes P, Zhang J, Li H, Struble C, Miller PE, Robinson MR. Lee SS, et al. Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19. Vet Ophthalmol. 2018. PMID: 29457333 Clinical Trial.
OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs. ...Baseline mean IOP in eyes treated with Bimatoprost SR was 14.9 mmHg, and a steady IOP reduction …
OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral veno …
Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost.
Nouh AH, Behairy AAE, El-Koumy FB, Aal AMA, Zhuravlova MS. Nouh AH, et al. Arch Dermatol Res. 2025 Apr 19;317(1):723. doi: 10.1007/s00403-025-04183-1. Arch Dermatol Res. 2025. PMID: 40252129 Clinical Trial.
This study evaluates the efficacy and safety of a novel therapeutic combination: CO2 fractional laser therapy with Bimatoprost 0.03% solution application. Conducted at Al-Azhar University Hospital between January 2019 and May 2023, the study involved 60 patients with clini …
This study evaluates the efficacy and safety of a novel therapeutic combination: CO2 fractional laser therapy with Bimatoprost 0.03% …
Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.
Fang Y, Ling Z, Sun X. Fang Y, et al. Drug Des Devel Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25999695 Free PMC article. Review.
Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People's Republic of China. BTFC has achieved good efficacy and tolerability in Chinese clinical trials. ...
Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People's Republic of China …
Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality.
Gupta AK, Bamimore MA, Foley KA. Gupta AK, et al. J Dermatolog Treat. 2022 Feb;33(1):62-72. doi: 10.1080/09546634.2020.1749547. Epub 2020 Apr 13. J Dermatolog Treat. 2022. PMID: 32250713 Free article.
We identified the following treatments for male AGA in decreasing rank of efficacy: platelet-rich plasma (PRP), low-level laser therapy (LLLT), 0.5 mg dutasteride, 1 mg finasteride, 5% minoxidil, 2% minoxidil, and bimatoprost. For female AGA the following were identified i …
We identified the following treatments for male AGA in decreasing rank of efficacy: platelet-rich plasma (PRP), low-level laser therapy (LLL …
Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial.
Muñoz-Negrete FJ, Topouzis F, Oddone F, Nisslé S, Rokicki D, Januleviciene I, Harasymowycz P, Stalmans I. Muñoz-Negrete FJ, et al. J Glaucoma. 2024 Jun 1;33(6):422-430. doi: 10.1097/IJG.0000000000002371. Epub 2024 Mar 4. J Glaucoma. 2024. PMID: 38506750 Free PMC article. Clinical Trial.
PRECIS: Noninferiority of efficacy was demonstrated for a preservative-free bimatoprost 0.01% compared with BAK-containing bimatoprost 0.01% following a 12-week treatment period in patients with open angle glaucoma or ocular hypertension. ...PURPOSE: To evaluate the …
PRECIS: Noninferiority of efficacy was demonstrated for a preservative-free bimatoprost 0.01% compared with BAK-containing bimatop …
212 results